QQQ   361.26 (+0.83%)
AAPL   173.75 (+1.48%)
MSFT   321.80 (+1.92%)
META   306.82 (+2.20%)
GOOGL   134.17 (+2.53%)
AMZN   129.46 (+1.84%)
TSLA   251.60 (+0.55%)
NVDA   447.82 (+2.95%)
NIO   8.79 (-2.77%)
BABA   86.53 (-0.24%)
AMD   103.27 (+0.44%)
T   14.67 (-2.33%)
F   12.31 (-0.97%)
MU   67.96 (-0.10%)
CGC   0.74 (-6.35%)
GE   108.79 (-1.59%)
DIS   81.67 (+0.76%)
AMC   8.16 (+2.00%)
PFE   33.94 (+2.32%)
PYPL   58.56 (+0.17%)
NFLX   380.33 (+0.72%)
QQQ   361.26 (+0.83%)
AAPL   173.75 (+1.48%)
MSFT   321.80 (+1.92%)
META   306.82 (+2.20%)
GOOGL   134.17 (+2.53%)
AMZN   129.46 (+1.84%)
TSLA   251.60 (+0.55%)
NVDA   447.82 (+2.95%)
NIO   8.79 (-2.77%)
BABA   86.53 (-0.24%)
AMD   103.27 (+0.44%)
T   14.67 (-2.33%)
F   12.31 (-0.97%)
MU   67.96 (-0.10%)
CGC   0.74 (-6.35%)
GE   108.79 (-1.59%)
DIS   81.67 (+0.76%)
AMC   8.16 (+2.00%)
PFE   33.94 (+2.32%)
PYPL   58.56 (+0.17%)
NFLX   380.33 (+0.72%)
QQQ   361.26 (+0.83%)
AAPL   173.75 (+1.48%)
MSFT   321.80 (+1.92%)
META   306.82 (+2.20%)
GOOGL   134.17 (+2.53%)
AMZN   129.46 (+1.84%)
TSLA   251.60 (+0.55%)
NVDA   447.82 (+2.95%)
NIO   8.79 (-2.77%)
BABA   86.53 (-0.24%)
AMD   103.27 (+0.44%)
T   14.67 (-2.33%)
F   12.31 (-0.97%)
MU   67.96 (-0.10%)
CGC   0.74 (-6.35%)
GE   108.79 (-1.59%)
DIS   81.67 (+0.76%)
AMC   8.16 (+2.00%)
PFE   33.94 (+2.32%)
PYPL   58.56 (+0.17%)
NFLX   380.33 (+0.72%)
QQQ   361.26 (+0.83%)
AAPL   173.75 (+1.48%)
MSFT   321.80 (+1.92%)
META   306.82 (+2.20%)
GOOGL   134.17 (+2.53%)
AMZN   129.46 (+1.84%)
TSLA   251.60 (+0.55%)
NVDA   447.82 (+2.95%)
NIO   8.79 (-2.77%)
BABA   86.53 (-0.24%)
AMD   103.27 (+0.44%)
T   14.67 (-2.33%)
F   12.31 (-0.97%)
MU   67.96 (-0.10%)
CGC   0.74 (-6.35%)
GE   108.79 (-1.59%)
DIS   81.67 (+0.76%)
AMC   8.16 (+2.00%)
PFE   33.94 (+2.32%)
PYPL   58.56 (+0.17%)
NFLX   380.33 (+0.72%)
NASDAQ:TCRR

TCR2 Therapeutics (TCRR) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$1.48
▼
$1.63
50-Day Range
$1.48
▼
$1.98
52-Week Range
$0.82
▼
$3.88
Volume
3.91 million shs
Average Volume
494,777 shs
Market Capitalization
$58.10 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.91
ProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability

TCR2 Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.14 Rating Score
Upside/​Downside
232.0% Upside
$4.91 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
-0.65
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.68) to ($0.79) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.47 out of 5 stars

Medical Sector

196th out of 975 stocks

Biological Products, Except Diagnostic Industry

26th out of 158 stocks

See Top Rated MarketRank™ Stocks Here

TCRR stock logo

About TCR2 Therapeutics (NASDAQ:TCRR) Stock

TCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. It is also involved in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development. The company was founded by Patrick A. Baeuerle on May 29, 2015 and is headquartered in Cambridge, MA.


TCRR Stock News Headlines

June 20, 2023 | wsj.com
DICE Therapeutics Inc.
June 1, 2023 | finance.yahoo.com
Adaptimmune Announces Completion of Strategic Combination with TCR2 Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
October 2, 2023 | Behind the Markets (Ad)
U.S. Loses to China in Shocking WAR GAMES
=== BREAKING === U.S. Loses to China in Shocking WAR GAMES Pentagon says new "living missile" key to winning a future conflict. Investors stand to reap 35,960% on shares of the small defense contractor that makes powerful new weapon. Get the name of the stock here >>>
May 16, 2023 | benzinga.com
TCR2 Therapeutics Insider Trades Send a Signal
May 12, 2023 | msn.com
Recap: TCR2 Therapeutics Q1 Earnings
May 11, 2023 | marketwatch.com
10-Q: TCR2 THERAPEUTICS INC.
May 11, 2023 | finance.yahoo.com
TCR² Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
April 15, 2023 | finance.yahoo.com
Companies Like TCR2 Therapeutics (NASDAQ:TCRR) Could Be Quite Risky
October 2, 2023 | Behind the Markets (Ad)
U.S. Loses to China in Shocking WAR GAMES
=== BREAKING === U.S. Loses to China in Shocking WAR GAMES Pentagon says new "living missile" key to winning a future conflict. Investors stand to reap 35,960% on shares of the small defense contractor that makes powerful new weapon. Get the name of the stock here >>>
March 25, 2023 | msn.com
Mizuho Downgrades Tcr2 Therapeutics (TCRR)
March 23, 2023 | markets.businessinsider.com
TCR2 Therapeutics (TCRR) was downgraded to a Hold Rating at Mizuho Securities
March 23, 2023 | markets.businessinsider.com
Analysts Offer Insights on Healthcare Companies: TCR2 Therapeutics (TCRR) and Inozyme Pharma (INZY)
March 23, 2023 | finanznachrichten.de
TCR2 Therapeutics: TCR² Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update
March 23, 2023 | finance.yahoo.com
TCR² Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update
March 9, 2023 | msn.com
What To Know About Jefferies's Downgrade of TCR2 Therapeutics
March 9, 2023 | markets.businessinsider.com
4 Analysts Have This to Say About TCR2 Therapeutics
March 8, 2023 | markets.businessinsider.com
TCR2 Therapeutics (TCRR) was downgraded to a Hold Rating at H.C. Wainwright
March 6, 2023 | benzinga.com
Shareholder Alert: Ademi LLP investigates whether TCR² Therapeutics Inc. has obtained a Fair Price in its transaction with Adaptimmune
March 6, 2023 | benzinga.com
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating TCR² Therapeutics Inc. Buyout
March 6, 2023 | investorplace.com
Why Is TCR2 Therapeutics (TCRR) Stock Up 30% Today?
March 6, 2023 | finanznachrichten.de
TCR2 Therapeutics: Adaptimmune and TCR² Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors
March 6, 2023 | markets.businessinsider.com
Adaptimmune To Combine With TCR² In All-stock Deal - Quick Facts
March 6, 2023 | finance.yahoo.com
Adaptimmune and TCR² Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors
March 6, 2023 | finance.yahoo.com
Adaptimmune and TCR2 Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors
February 16, 2023 | benzinga.com
TCR2 Therapeutics Stock (NASDAQ:TCRR), Quotes and News Summary
February 8, 2023 | finance.yahoo.com
TCR² Therapeutics to Present at SVB Securities Global Biopharma Conference 2023
January 18, 2023 | reuters.com
TCRR.C - | Stock Price & Latest News | Reuters
See More Headlines
Receive TCRR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TCR2 Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TCRR Company Calendar

Last Earnings
11/10/2021
Today
10/02/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TCRR
CUSIP
N/A
CIK
1750019
Web
www.tcr2.com
Phone
(617) 949-5200
Fax
N/A
Employees
137
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$4.91
High Stock Price Forecast
$13.00
Low Stock Price Forecast
$1.68
Forecasted Upside/Downside
+232.0%
Consensus Rating
Hold
Rating Score (0-4)
2.14
Research Coverage
7 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($4.20)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-151,820,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-97.81%
Return on Assets
-69.35%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.96
Quick Ratio
2.96

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.58 per share
Price / Book
0.57

Miscellaneous

Outstanding Shares
39,260,000
Free Float
29,443,000
Market Cap
$58.10 million
Optionable
Not Optionable
Beta
1.95
The Best High-Yield Dividend Stocks for 2023 Cover
The Best High-Yield Dividend Stocks for 2023

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Garry E. Menzel
    President, Chief Executive Officer & Director
  • Peter Olagunju
    Chief Operating Officer
  • Eric M. Sullivan
    Chief Financial Officer
  • Alfonso Quintás-Cardama
    Chief Medical Officer
  • Praveen Malhotra
    Vice President-Information Technology

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













TCRR Stock - Frequently Asked Questions

Should I buy or sell TCR2 Therapeutics stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for TCR2 Therapeutics in the last year. There are currently 6 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" TCRR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TCRR, but not buy additional shares or sell existing shares.
View TCRR analyst ratings or view top-rated stocks.

What is TCR2 Therapeutics' stock price forecast for 2023?

7 equities research analysts have issued 1-year price targets for TCR2 Therapeutics' shares. Their TCRR share price forecasts range from $1.68 to $13.00. On average, they predict the company's share price to reach $4.91 in the next year. This suggests a possible upside of 232.0% from the stock's current price.
View analysts price targets for TCRR or view top-rated stocks among Wall Street analysts.

How were TCR2 Therapeutics' earnings last quarter?

TCR2 Therapeutics Inc. (NASDAQ:TCRR) posted its earnings results on Wednesday, November, 10th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.63) by $0.06.

What other stocks do shareholders of TCR2 Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TCR2 Therapeutics investors own include Editas Medicine (EDIT), Gossamer Bio (GOSS), Alector (ALEC), Kaleido Biosciences (KLDO), Precision BioSciences (DTIL), Homology Medicines (FIXX), LogicBio Therapeutics (LOGC), Sorrento Therapeutics (SRNE), Atreca (BCEL) and II-VI (IIVI).

When did TCR2 Therapeutics IPO?

(TCRR) raised $76 million in an IPO on Thursday, February 14th 2019. The company issued 5,000,000 shares at a price of $14.55-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO and Wedbush PacGrow and China Renaissance were co-managers.

What is TCR2 Therapeutics' stock symbol?

TCR2 Therapeutics trades on the NASDAQ under the ticker symbol "TCRR."

What is TCR2 Therapeutics' stock price today?

One share of TCRR stock can currently be purchased for approximately $1.48.

How much money does TCR2 Therapeutics make?

TCR2 Therapeutics (NASDAQ:TCRR) has a market capitalization of $58.10 million. The company earns $-151,820,000.00 in net income (profit) each year or ($4.20) on an earnings per share basis.

How many employees does TCR2 Therapeutics have?

The company employs 137 workers across the globe.

How can I contact TCR2 Therapeutics?

TCR2 Therapeutics' mailing address is 100 BINNEY STREET SUITE 710, CAMBRIDGE MA, 02142. The official website for the company is www.tcr2.com. The company can be reached via phone at (617) 949-5200 or via email at investors@tcr2.com.

This page (NASDAQ:TCRR) was last updated on 10/2/2023 by MarketBeat.com Staff

My Account -